Recent advancements in pharmaceuticals, particularly in cell and gene therapies (C>s), monoclonal antibody (mAb) treatments, and advanced therapy medicinal products (ATMPs), have greatly enhanced patient care.However, the substantial costs involved in developing and manufacturing these cutting-edge treatments limit their availability to a broader population.